Five blockbuster candidates less than two years away, says Novartis

At an investor event at its US R&D base, Swiss pharma giant Novartis (NOVN: VX) has reiterated its strategy to “become a leading medicines company powered by advanced therapy platforms and data science.”

Chief executive Vas Narasimhan said the firm was “on track to deliver sustained accretive growth,” adding that its pipeline was “industry-leading.”

Executives highlighted what they saw as the continued strength of interleukin (IL)-17 blocker Cosentyx (secukinumab) and heart med Entresto (sacubitril/valsartan), including new data from the PIONEER study which will support hospital initiation of the latter product.